Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection

Canadian Journal of Gastroenterology

Volumn 24, Issue 5, 2010, Pages 303-306

  Veldhuyzen Van Zanten, Sander ^a   Desai, Snehal ^b   Best, Linda ^b   Cooper Lesins, Geraldine ^b   Malatjalian, Dickran ^b   Haldane, David ^b   Peltekian, Kevork ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Amoxicillin; Antibiotic resistance; Clarithromycin; Eradication rate; Helicobacter pylori; Metronidazole; Proton pump inhibitor; Rifabutin; Treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; ENDOSCOPIC BIOPSY; EPSILOMETER TEST; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; MALE; PRIORITY JOURNAL; UREA BREATH TEST;

EID: 77952310695     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/637908     Document Type: Article

References (38)

1. Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: A meta-analysis. Int J Epidemiol 2002;31:128-139
2. Rodgers C, Veldhuyzen van Zanten S. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol 2007;21:295-300.
3. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
4. Nash C, Best T, Haldane H, Malatjalian D, Veldhuyzen van Zanten S. Results of PPI-based triple therapies or PPI-based quadruple therapies for cure of H pylori infection in Halifax. Can J Gastroenterol 2002;16(Suppl A):114.
5. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-469
6. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996;22(Suppl 1):S3-13.
7. Akada JK, Shirai M, Fujii K, Okita K, Nakazawa T. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother 1999;43:1072-1076
8. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-1499
9. Perri F, Vesta V, Andruilli A. Treatment of antibiotic resistant Helicobacter pylori. N Engl J Med 1998;339:53.
10. Perri F, Vesta V, Clemente R, et al. Rifabutin based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316
11. Bock H, Koop H, Lehn N, et al. Rifabutin based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience. J Clin Gastroenterol 2000;31:222-225
12. Perri F, Vesta V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
13. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin, and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-560
14. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94
15. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395-403.
16. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:481-488
17. Navarro-Jarabo JM, Fernández N, Sousa FL, et al. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection. BMC Gastroenterol 2007;7:31.
18. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: A 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-354
19. Best LM, Haldane DJ, Veldhuyzen van Zanten SJ, et al. Multilaboratory comparison of profiencies in susceptibility testing of Helicobacter pylori and correlation between Agar dilution and E test methods. Antimicrob Agents Chemother 2003;47:3130-3137
20. Cave DR, Veldhuyzen van Zanten SJ, Carter E, et al. A multicentre evaluation of the laser associated ratio analyzer (LARA): A novel device for measurement of 13C urea breath test for detection of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:747-752
21. Mock T, Yatscoff R, Foster R, et al. Clinical validation of the Helikit: A 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Clin Biochem 1999;32:59-63.
22. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007;26:1537-1542
23. Koudriakova T, Iatsimirskaia E, Tulebaev S, et al. In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 1996;279:1300-1309
24. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107.
25. Gisbert JP, Boixeda D, Bermejo F, et al. Retreatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11:1049-1054
26. Nagahara A, Miwa H, Okhura R, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16:613-618
27. Gisbert JP, Pajares JM. Helicobacter pylori rescue regimen when proton pump inhibitor based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057
28. Nash C, Fischbach L, Veldhuyzen van Zanten SJO. What are the global response rates to Helicobacter pylori eradication therapy? Can J Gastroenterology 2003;17(Suppl B):25-29B.
29. Suzuki S, Suzuki H, Nishizawa T, et al. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion 2009;79:1-4.
30. Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high dose rifabutin in macrolide containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;231:594-598
31. Apseloff G, Feulds G, Laboy-Goral L, et al. Severe neutropenia caused by recommended prophylactic doses of rifabutin. Lancet 1996;348:685. (Pubitemid 26293827)
32. Gisbert JP, Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
33. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM.Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006;24:1469-1474 (Pubitemid 44657124)
34. Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008;13:69-74.
35. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 2007;146:556-563
36. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis. Gut 2008;57:1178.
37. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: A 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-354
38. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-25